Packed Red Blood Cells Accumulate Oxidative Stress With Increased Storage Duration

Preston, Kelsey; Harm, Sarah; Dreyfus, Nathan; Villalba, Nuria; Freeman, Kalev

doi:10.1097/shk.0000000000000828

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A potential explanation would be that sAML probably received blood transfusions before the final diagnosis of sAML was achieved, and it has been demonstrated that transfusions with packed red blood cells as well as platelet concentrates can increase the concentrations of OS markers in AML [ 30 ]. In addition, the storage of blood products is linked to an elevation in OS, and the use of transfusions is correlated with an elevation in iron stores as well as iron overload, which can interfere with the crosstalk of ROS and pro-inflammatory cytokines, leading to an increase in OS in both benign and malignant hematological disorders [ 31 , 32 ]. Similarly, patients diagnosed with PMF are also prone to receive blood transfusions, particularly if they are prescribed drugs such as ruxolitinib or hydroxyurea, which can lead to hematological toxicities, e.g., anemia.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Total Antioxidant Capacity, 8-Hydroxy-2′-deoxy-guanosine, the Genetic Landscape, and Their Associations in BCR::ABL-1-Negative Chronic and Blast Phase Myeloproliferative Neoplasms

Găman,

Mambet,

Neagu

et al. 2024

IJMS

View full text Add to dashboard Cite

Myeloproliferative neoplasms (MPNs), namely, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are clonal stem cell disorders defined by an excessive production of functionally mature and terminally differentiated myeloid cells. MPNs can transform into secondary acute myeloid leukemia (sAML/blast phase MPN) and are linked to alterations in the redox balance, i.e., elevated concentrations of reactive oxygen species and markers of oxidative stress (OS), and changes in antioxidant systems. We evaluated OS in 117 chronic phase MPNs and 21 sAML cases versus controls by measuring total antioxidant capacity (TAC) and 8-hydroxy-2′-deoxy-guanosine (8-OHdG) concentrations. TAC was higher in MPNs than controls (p = 0.03), particularly in ET (p = 0.04) and PMF (p = 0.01). MPL W515L-positive MPNs had higher TAC than controls (p = 0.002) and triple-negative MPNs (p = 0.01). PMF patients who had treatment expressed lower TAC than therapy-free subjects (p = 0.03). 8-OHdG concentrations were similar between controls and MPNs, controls and sAML, and MPNs and sAML. We noted associations between TAC and MPNs (OR = 1.82; p = 0.05), i.e., ET (OR = 2.36; p = 0.03) and PMF (OR = 2.11; p = 0.03), but not sAML. 8-OHdG concentrations were not associated with MPNs (OR = 1.73; p = 0.62) or sAML (OR = 1.89; p = 0.49). In conclusion, we detected redox imbalances in MPNs based on disease subtype, driver mutations, and treatment history.

show abstract

Section: Discussionmentioning

confidence: 99%